Blog
RSS FeedPosted by Michael Wonder on 03 Apr 2019
Institute for Clinical and Economic Review Appoints Dr. Pamela Bradt as Chief Scientific Officer
2 April 2019 - The Institute for Clinical and Economic Review has announced the appointment of Pamela Bradt as the organization's ...
Posted by Michael Wonder on 23 Mar 2019
Senate panel to hear from pharmacy middlemen on drug prices
21 March 2019 - The Senate Finance Committee said Thursday that it has secured commitments from executives of five major ...
Posted by Michael Wonder on 19 Mar 2019
Institute for Clinical and Economic Review appoints new members to each of its three independent evidence appraisal councils
18 March 2019 - New members bring expertise in broad range of perspectives, including patient advocacy, health policy, economics, and clinical ...
Posted by Michael Wonder on 12 Mar 2019
Cancer Institute's Sharpless tapped as acting chief of FDA
12 March 2019 - Ned Sharpless, the director of the National Cancer Institute, will be named temporary chief of the ...
Posted by Michael Wonder on 06 Mar 2019
Donald Trump just lost his most popular bureaucrat
6 March 2019 - U.S. FDA Commissioner Scott Gottlieb is resigning and will leave the agency in a month, according to ...
Posted by Michael Wonder on 06 Mar 2019
FDA chief tough on e-cigs steps down in surprise resignation
5 March 2019 - U.S. FDA Commissioner Scott Gottlieb said on Tuesday that he plans to step down next month, a ...
Posted by Michael Wonder on 31 Jan 2019
CEOs hide as pressure on drug prices grows
30 January 2019 - This week, key committees in the House and Senate each held hearings on the rising cost ...
Posted by Michael Wonder on 16 Jan 2019
The FDA has five weeks till money runs out for approving new drugs
16 January 2019 - The US FDA has roughly five weeks of funding left to review new drug applications during ...
Posted by Michael Wonder on 16 Jan 2019
EMA to lose 25% of staff as hard Brexit approaches
14 January 2019 - As UK Prime Minister Theresa May’s Brexit deal is expected to be rejected Tuesday in a ...
Posted by Michael Wonder on 15 Jan 2019
If the shutdown drags on at FDA, it will put anticipated new treatments in jeopardy
14 January 2019 - The government shutdown could soon jeopardise highly anticipated new drugs from Janssen, Sanofi, and Novartis for ...
Posted by Michael Wonder on 14 Jan 2019
Cost recovery and Pharmaceutical Benefits Scheme process improvements information forums
14 January 2019 - The Department of Health will be hosting information forums in both Sydney and Melbourne regarding amendments ...
Posted by Michael Wonder on 11 Jan 2019
Partial government shutdown's impact on FDA drug approvals
10 January 2019 - As the partial federal government shutdown drags on into its third week, its impact is being felt ...
Posted by Michael Wonder on 08 Jan 2019
All seven of the FDA’s recent commissioners agree it should be independent — but not on how to accomplish it
7 January 2019 - Nearly every person who’s run the FDA in recent history agrees the agency should break free ...
Posted by Michael Wonder on 08 Jan 2019
FDA plans to create a new office to leverage cutting-edge science
7 January 2019 - The FDA plans to create a new office to improve the review of new medicines — ...
Posted by Michael Wonder on 02 Jan 2019
Department update: implementation of the improved payment administration arrangements
2 January 2019 - A communique describing key achievements for 2018, and important next steps for 2019 is now available on ...